Virpax Pharmaceuticals

Virpax Pharmaceuticals Expands AnQlar Development, Commercialization Rights Through Worldwide Licensing Agreement

BERWYN, PA — Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) recently expanded its exclusive license agreement for AnQlar™ with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.

Virpax Pharmaceuticals Expands AnQlar Development, Commercialization Rights Through Worldwide Licensing Agreement Read More